Rhythm Pharmaceuticals (RYTM) Update / Briefing July 09, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Top Line Results from Phase II Trial Evaluating Bivamilagon in Acquired Hypothalamic Obesity Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask the questions in the session, you will need to press 11 on your telephone. You will then hear an auto ...

Rhythm Pharmaceuticals (RYTM) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 Okay. Yeah. Hi. Hi, good afternoon. Welcome to day one of the Jefferies Healthcare Conference. My name is Dennis Ting, biotech analyst here at Jefferies. I have the great pleasure of having CEO David Meeker here with us from Rhythm Pharmaceuticals. Welcome. Speaker1 Yeah. Thanks, Dennis. Speaker0 So perhaps just level set us in terms of where the company is today and just sort of the evolution of the company since over the last ...

Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants David Connolly - Executive Director, Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, President & CEOJennifer Lee - Executive Vice President, Head of North AmericaYann Mazabraud - Executive VP & Head of InternationalHunter Smith - Chief Financial OfficerJon Wolleben - Managing DirectorTazeen Ahmad - MD - US Equity ResearchSeamus Fernandez - Senior Managing DirectorWhitney Ijem - Managing ...

Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question and answer session. I would now like to hand the conference over to your speaker today, David Connolly, Investo ...